Cargando…
Retinoic acid-induced CHD5 upregulation and neuronal differentiation of neuroblastoma
BACKGROUND: Chromodomain-helicase DNA binding protein 5 (CHD5) is an important tumor suppressor gene deleted from 1p36.31 in neuroblastomas (NBs). High CHD5 expression is associated with a favorable prognosis, but deletion or low expression is frequent in high-risk tumors. We explored the role of CH...
Autores principales: | Higashi, Mayumi, Kolla, Venkatadri, Iyer, Radhika, Naraparaju, Koumudi, Zhuang, Tiangang, Kolla, Sriharsha, Brodeur, Garrett M. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4527355/ https://www.ncbi.nlm.nih.gov/pubmed/26245651 http://dx.doi.org/10.1186/s12943-015-0425-y |
Ejemplares similares
-
Role of microRNAs in epigenetic silencing of the CHD5 tumor suppressor gene in neuroblastomas
por: Naraparaju, Koumudi, et al.
Publicado: (2016) -
CHD5, a Tumor Suppressor Gene Deleted From 1p36.31 in Neuroblastomas
por: Fujita, Tomoyuki, et al.
Publicado: (2008) -
Nanomicellar Lenalidomide–Fenretinide Combination Suppresses Tumor Growth in an MYCN Amplified Neuroblastoma Tumor
por: Orienti, Isabella, et al.
Publicado: (2020) -
A Novel Nanomicellar Combination of Fenretinide and Lenalidomide Shows Marked Antitumor Activity in a Neuroblastoma Xenograft Model
por: Orienti, Isabella, et al.
Publicado: (2019) -
Poloxamer‐linked prodrug of a topoisomerase I inhibitor SN22 shows efficacy in models of high‐risk neuroblastoma with primary and acquired chemoresistance
por: Alferiev, Ivan S., et al.
Publicado: (2022)